Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Mallinckrodt
McKesson
AstraZeneca

Last Updated: January 27, 2022

Volunteer for clinical trials for MOVANTIK at ClinicalTrialExchange

DrugPatentWatch Database Preview

MOVANTIK Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Movantik, and when can generic versions of Movantik launch?

Movantik is a drug marketed by Redhill and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fourteen patent family members in forty-one countries.

The generic ingredient in MOVANTIK is naloxegol oxalate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.

DrugPatentWatch® Generic Entry Outlook for Movantik

Movantik was eligible for patent challenges on September 16, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 2, 2032. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for MOVANTIK
Drug Prices for MOVANTIK

See drug prices for MOVANTIK

DrugPatentWatch® Estimated Generic Entry Opportunity Date for MOVANTIK
Generic Entry Date for MOVANTIK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MOVANTIK

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Missouri-ColumbiaPhase 4
University of Tennessee, ChattanoogaN/A
Camille Ladanyi MDN/A

See all MOVANTIK clinical trials

Pharmacology for MOVANTIK
Drug ClassOpioid Antagonist
Mechanism of Action Opioid Antagonists
Paragraph IV (Patent) Challenges for MOVANTIK
Tradename Dosage Ingredient NDA Submissiondate
MOVANTIK TABLET;ORAL naloxegol oxalate 204760 2018-09-17

US Patents and Regulatory Information for MOVANTIK

MOVANTIK is protected by six US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of MOVANTIK is ⤷  Try it Free.

This potential generic entry date is based on patent ⤷  Try it Free.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting MOVANTIK

Polymer conjugates of opioid antagonists
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Polymer conjugates of opioid antagonists
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Chemically modified small molecules
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Chemically modified small molecules
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Polymer conjugates of opioid antagonists
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Crystalline naloxol-peg conjugate
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for MOVANTIK

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1694363 PA2015019,C1694363 Lithuania ⤷  Try it Free PRODUCT NAME: NALOKSEGOLAS, KONKRECIAI NALOKSEGOLO OKSALATO DRUSKA; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363 27/2015 Austria ⤷  Try it Free PRODUCT NAME: NALOXEGOL, GEGEBENENFALLS IN FORM EINES THERAPEUTISCH VERTRAEGLICHEN SALZES, INSBESONDERE ALS OXALAT; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363 C300737 Netherlands ⤷  Try it Free PRODUCT NAME: NALOXEGOL ALSMEDE DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363 592 Finland ⤷  Try it Free
1694363 PA2015019 Lithuania ⤷  Try it Free PRODUCT NAME: NALOXEGOLUM; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363 SPC/GB15/026 United Kingdom ⤷  Try it Free PRODUCT NAME: NALOXEGOL OXALATE; REGISTERED: UK EU/1/14/962/001-011 20141210
1694363 2015/024 Ireland ⤷  Try it Free PRODUCT NAME: NALOXEGOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE OXALATE SALT OF THE ALPHA-EPIMER OF NALOXEGOL; REGISTRATION NO/DATE: EU/1/14/962 20141208
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
Express Scripts
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.